raloxifene has been researched along with Experimental Mammary Neoplasms in 1 studies
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, CD | 1 |
| Jevnikar, MG | 1 |
| Pike, AJ | 1 |
| Peters, MK | 1 |
| Black, LJ | 1 |
| Thompson, AR | 1 |
| Falcone, JF | 1 |
| Clemens, JA | 1 |
1 other study available for raloxifene and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Estrogen Antagonists; Female; Mammary Neoplasms, Experime | 1984 |